Acute promyelocytic leukaemia (APL) is a well-defined disease characterized by a typical morphology of leukaemic cells, the presence of t(15;17) translocation and the unique sensitivity to the differentiating effect of all-trans retinoic acid. Nevertheless, some aspects are variable among APL patients, with differences substantially related to morphological variants, peripheral leukocytes count, the presence of a disseminated intravascular coagulopathy, different PML/RARa isoforms (long, variable or short) and Fms-like tyrosine kinase 3 (Flt3) mutations. In order to better define this variability, we investigated the gene expression profiles of 18 APL cases revealing, besides a high uniformity in gene expression pattern, the presence of few robust differences among patients able to identify, by an unsupervised analysis, two major clusters of patients characterized by different phenotypes (hypogranular M3v vs classical M3) and by the presence or absence of Flt3 internal tandem duplications (ITDs). Further supervised analysis confirmed that Flt3 status was the APL parameter best associated with these two subgroups. We identified, between Flt3 wild-type and Flt3-ITDs subsets, 147 differentially expressed genes that were involved in the cytoskeleton organization, in the cell adhesion and migration, in the proliferation and the coagulation/inflammation pathways as well as in differentiation and myeloid granules constitution suggesting a role of Flt3 mutations in the pathogenesis and clinical manifestations of APL.
Introduction
Acute promyelocytic leukaemia (APL) represents approximately 10-15% of acute myeloid leukaemias (AMLs) and is considered a unique disease clearly distinguishable from the other types of AMLs. In fact, APL is characterized by the presence of a serious haemorrhagic syndrome due to disseminated intravascular coagulopathy and fibrinolysis at the onset, a promyelocytic-like morphologic aspect of leukaemic blast cells, a very specific molecular lesion ever involving the RARa gene and a very effective therapy represented by all-trans retinoic acid (ATRA) which is able to determine the terminal differentiation of promyelocytic leukaemic cell. 1 Recently, gene expression profiling studies have also confirmed a unique expression pattern in APL cases which can be clearly identified among the other AMLs. [2] [3] [4] Nevertheless, there are some aspects which vary among APL patients and which have been correlated with different clinical manifestations of the disease. First, besides cases with the classical morphologic type, characterized by blast cells with heavy azurophilic granules, bundles of Auer rods and reniform or bilobated nuclei, also known as hypergranular form and identified by the FAB cooperative group as M3-AML, about 15-20% of cases show a hypogranular or microgranular APL variant form (M3v-AML), in which the majority of blast cells have a typical bilobated nucleus and are devoid or contain only a few cytoplasmic granules. 5 Besides this, other aspects appear to vary among APL patients: peripheral white cell count at diagnosis is increased in only a minority of patients, mostly related to the M3v subtype and currently considered an adverse prognostic indicator. Moreover, due to the variable breakpoint on the PML gene that is involved in the t(15;17) translocation, a long, a variable and a short form of the PML/RARa chimeric transcript have been recognized and examined for their prognostic importance. Although, more relevant, the great majority of APL patients experience a long-term remission, a significant number of them, equal to 20-30%, die due to early haemorrhagic complication or to leukaemia relapse.
Although APL cells invariably express aberrant fusion proteins involving the RARa gene, mainly joined with the PML gene, all PML/RARa transgenic mice develop a nonfatal myeloproliferative disorder but only a minority of them, about 15%, develop an APL-like disease after a long latency period, suggesting that additional mutations are required to develop APL. [6] [7] [8] A candidate gene to play such a role is the Fms-like tyrosine kinase 3 (Flt3) gene, a receptor tyrosine kinase (RTK) belonging to type III family, along with c-kit, c-fms and PDGFRa and b. Mutations, leading to a constitutive activation of the Flt3 receptor kinase, are found in about one-quarter of all AMLs and are considered the most common genetic alterations in human acute leukaemia. In particular, internal tandem duplications (ITDs) or point mutation within the activation loop (ALM) of the tyrosine kinase domain 2 (TKD2) of Flt3 seem to be present at an even higher frequency (35-40%) in human APL cases. 9, 10 Interestingly, PML/RARa and Flt3-ITDs have been shown to cooperate in the induction of an APL-like phenotype in PML/RARa transgenic mice subjected to transplantation with BM cells retrovirally transfected with Flt3-ITD. 11 Associations between Flt3 mutations and clinical or molecular characteristics of APL have been found, and in particular a high white blood cell count, M3v morphology and the presence of the short PML/ RARa isoform were reported to be related to Flt3-ITDs. 12 On the contrary, a prognostic role of Flt3 mutations was not clearly defined in APL patients, although an inferior overall survival trend was observed. 13 In this study, we analysed the gene expression profiles of 18 APL patients using a high density DNA-oligonucleotide microarray (Agilent) representing about 20 000 genes and demonstrated the presence of a very uniform expression pattern in APL cases among which however two main APL subtypes were recognized by unsupervised analysis. Relationship between these two subgroups and the different clinical, haematological and molecular APL features, comprising Flt3 status, were investigated.
Materials and methods

APL patients and samples
In total, 29 patients newly diagnosed with APL and treated according to the AIDA protocol 14 were studied. The median age at diagnosis was 60 years with a range of 22-83 years. Bone marrow (BM) samples were obtained at diagnosis. APL was morphologically diagnosed according to the FAB classification and confirmed by immunophenotyping, standard cytogenetic and RT-polymerase chain reaction (PCR) detection of PML/RARa fusion transcripts. 15 The different PML/RARa isoforms were also determined: 15 cases had bcr1, 13 had bcr3 and one case had bcr2 breakpoint cluster region. A total of 18 BM samples showing high level of blast cells (at least 90%) and high-quality RNA were selected for gene expression analysis. Table 1 summarizes the patients' characteristics. All samples were enriched for the blast fraction using Lymphoprep (density 1.077 g/ml Nycomed) density gradient centrifugation. Genomic DNA was extracted using Easy-DNA kit (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturer's protocol. Total RNA was isolated using RNeasy Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions.
Analysis of the Flt3 status
To detect Flt3-ITDs, exons 14 and 15 covering the juxtamembrane domain (JMD) were amplified by PCR as described elsewhere. 16 ITDs were detected as an additional longer PCR product by 3% agarose gel electrophoresis and confirmed by direct sequencing. D835 and/or I836 mutations were analyzed by PCR amplification of exon 20, corresponding to TKD2, followed by EcoRV digestion and confirmed by direct sequencing as reported elsewhere. 17 
RNA reference
Universal Human Reference RNA (Stratagene, Cedar Creek, TX, USA), used as reference control in all microarray gene-profiling experiments, consisted of equal amount of total RNA from 10 human cancer cell lines. Amplified reference cRNA was labelled with cyanine 3-CTP (Perkin-Elmer, NEN Life Science, Boston, MA, USA) in each experiment.
Total RNA labelling and microarray hybridization
For all 18 selected RNAs for gene expression analysis, fluorescently labelled cRNA was generated by in vitro transcription using Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies, Palo Alto, CA, USA) according to the manufacturer's instructions. Amplified cRNA of each patient was labelled with cyanine 5-CTP (Perkin-Elmer, NEN Life Science, Boston, MA, USA) in each experiment. Moreover, cRNA products were purified using RNeasy columns (Qiagen). Samples had to contain 10-20 picomoles of cyanine dye/mg of cRNA to be considered suitable for subsequent hybridization. Cy5-labelled cRNA (1 mg) was mixed with the same amount of Cy3-labelled reference cRNA, and then mixed cRNAs were fragmented to an average size of B50-100 nt by incubation at 601C for 30 min using in situ hybridization kit-plus (Agilent). Samples were hybridized on Agilent Human 1A Oligo Microarray (V2), ink-jet printed microarray, comprising 20 173 (60-mer) experimentally validated oligonucleotide probes (features). 18 After hybridization for 17 h at 601C, slides were washed according to Agilent SSPE protocol instructions and then scanned using a confocal laser scanner (Agilent Technologies).
Data analysis and unsupervised clustering
Fluorescence data were analysed with Feature Extraction Software v7.5 (Agilent Technologies). Log 10 ratio of the dyenormalized Cy3 and Cy5 channel signals were calculated, then 19 
Supervised clustering
Supervised classification of APL samples into categories according to mutational status of Flt3 gene based on gene expression profiles was performed using Bayesian classifier implemented by Rosetta Biosoftware. This method includes the following three steps: (1) selection of candidate genes that are significantly different among relevant classes based on t-tests. Those features showing the larger t-values tend to carry more discriminating power than others. The features are selected with |t|X1; (2) probability computation, performed using a set of discriminant functions (d) derived from the posterior probabilities of the classes. These are used to estimate the relevant probability from the training set; (3) classification and classifier validation, in which each observation to be classified is assigned to a class i if its discriminative function value (d i ), given by the selected features, is higher than the one obtained for the second class. To estimate the quality of the classifier, the member of each training set was also reclassified (self-validation) and a leave-one-out crossvalidation was then performed. 20 Gene expression data were also analyzed using analysis of variance (ANOVA) implemented by Rosetta Biosoftware. To increase the statistical power, the enhanced ANOVA uses as input data both expression level and the estimated technology error associated with the expression level. As a result, the false-positive rate is reduced when the number of replicates is small and, then, sensitivity detection is increased. Our original m-dimensional data patterns were transformed to data patterns in a feature space with lower dimensionality using Principal Component Analysis (PCA). 21 
Statistical analysis
Data were analysed using SPSS for Windows Version 11.0. (SPSS Inc, Chicago, IL, USA). To determine significant differences in binary variables, the Pearson w 2 test or the Fisher exact test were used. Furthermore, group-wise comparisons of distributions of continuous variables were performed with Mann-Whitney nonparametric test. All were two-sided. An effect was considered statistically significant at Pp0.05.
Results
Analysis of Flt3 mutation status
We assessed the Flt3 mutation status in 29 adult patients with APL at the time of diagnosis. DNAs obtained from untreated BM samples were screened for the presence of Flt3-ITDs and for mutations in the activation loop (ALM) of TKD2. Overall, 12 APL patients (41.4%) carried Flt3 mutations (ITD and/or Asp835), whereas 17 APL patients (58.6%) showed Flt3 gene in a wild-type configuration (Flt3-WT group). Seven out of 29 APL patients (24.1%) had only ITDs length mutations (Flt3-ITD group). The size of length mutations varied from 18 to 93 bp (median 46.9 bp) and the reading frame was always maintained. As shown in Table 2 , Flt3-ITD group was significantly associated with a higher white blood cell count (WBC) (P ¼ 0.009) as well as with a higher circulating blast cell percentage (P ¼ 0.021). Moreover, the presence of ITDs in Flt3 gene was related to microgranular morphology (M3v) (Po0.0001) and short-type PML/RARa isoform (bcr3) (P ¼ 0.042), as previously described. 16, 22, 23 Flt3 activation loop mutations were present in five of 29 (17.2%) APL patients (Flt3-ALM group). We found the presence of a missense mutation at codon 835 in four cases and a six-base pair deletion together with a missense mutation at codon 836 in one case. Only one patient (case 21) harboured both ITDs and D835 mutation.
Identification of APL subsets by unsupervised hierarchical clustering
A total of 18 APL patients selected from our series for the high quality of total RNA were hybridized on Agilent microarray containing approximately 20 000 human genes. Flt3-ITDs and Flt3-ALMs were present in seven and three cases, respectively, Table 2 Comparisons of clinical parameters between FLT3-ITD and FLT3-WT groups Expression profiling and Flt3 status in APL R Marasca et al one patient had both Flt3 alterations and the remaining seven cases had Flt3-WT.
To identify biologically meaningful subsets of APL, resultant gene expression profiles were first analysed using an unsupervised, agglomerative hierarchical clustering with average link as heuristic criteria and correlation with mean subtraction as similarity metric. Before hierarchical clustering computation, some filters were applied on the data: only those genes showing a fold change greater than 3 and a P-valuep0.001 in at least one-third of the samples were selected. The two-dimensional matrix clearly showed the high grade of uniformity in gene expression pattern among APL patients, the majority of genes being expressed at high (red colour) or low (green colour) levels relative to reference in all APL cases analysed (Figure 1a) . Concordantly, this uniformity was revealed by the high correlation coefficient (Pearson correlation coefficient range: 0.90-0.98) measured between all the samples examined. This appearance of unsupervised matrix reflects the homogeneous nature of APL whose gene expression pattern definitely distinguishes it from all other types of acute myeloid leukaemia, as assessed previously. 2 Besides the homogeneous pattern, subtle robust differences in gene expression enabled the identification of three clusters of APL patients (designed I, II, III) (Figure 1b) . Clusters I and II consisted of nine and seven cases, respectively, whereas Cluster III had only two samples. Comparisons between Cluster I and Cluster II patients clearly revealed a preferential distribution of Flt3 gene-mutated cases in Cluster I (Table 3 ). The majority of Cluster I patients (88.9%) had mutated Flt3 gene, instead Cluster II patients mainly expressed Flt3 genes in wild-type configuration (71.4%). In particular, all Flt3-ITD patients clustered tightly in the same leftmost side (I), and all but one (case 19) Flt3-WT patients clustered in the righthand side of the dendrogram (II and III) (P ¼ 0.007). Three out of four Flt3-ALM cases were localized on the right branch of the dendrogram closer to Flt3-WT cases. Again, Cluster I was related to microgranular morphology (M3v) (P ¼ 0.035) and short-type PML/RARa isoform (bcr3) (P ¼ 0.044). In particular, 71.4% (n ¼ 5) of Cluster II had a classic APL morphology in contrast with only 11.1% of patients in Cluster I. Moreover, most cases harbouring t(15;17) breakpoint cluster region 3 belonged to Cluster I (80% of all bcr3 cases), whereas 80% of bcr1 belonged to Cluster II. Furthermore, as shown in Table 3 , Cluster I was significantly associated with higher circulant blast cell percentage (P ¼ 0.030) as well as hyperleukocytosis (P ¼ 0.009).
Gene expression variability between APL Clusters I and II is mainly associated to Flt3-ITDs
In order to identify the principal sources of gene expression variability within the two main APL subsets identified by unsupervised clustering, we extrapolated, applying ANOVA algorithm (excluding Cluster III cases), those genes (Po0.01). able to distinguish hypogranular from hypergranular morphological APL subsets (M3v signature), cases harbouring Flt3-ITDs from the others (ITD signature) and cases with different PML/ RARa isoforms (bcr signature). Overall, altered expression of 477 and 356 genes determined the variability linked to the two genetic features (Flt3-ITD and PML/RARa isoforms, respectively), whereas only 229 genes characterized the APL morphological phenotypes. Of note, 100 genes (44% of M3v signature) were shared between M3v morphology and Flt3-ITD signature, but only 37 and 25 differentially expressed genes of bcr signature were shared with ITD and M3v signatures (10 and 7% of bcr signature, respectively) (Figure 2a) . Full ANOVA gene lists are included in GEO web site (Supplements 1-6 ).
Moreover, we identified the differentially expressed genes able to characterize and thus distinguish APL Clusters I and II patients (Po0.01). Among 1477 genes found, 382 (26%) were common to ITD signature (80% of ITD signature). On the other hand, only 14% (216 genes) and 9% (136 genes) of differentially expressed genes were influenced by PML/RARa isoforms and by M3/M3v morphology, respectively. Furthermore, it is remarkable that when the analysis was restricted to the 349 genes with a higher statistical significance (Po0.0001) among differentially expressed genes in APL Clusters I and II, 171 genes (49%) were common to the ITD signature, and only 91 and 57 genes were related, respectively, to the bcr and M3v signatures (Figure 2b ). excluded) . First of all, 147 genes, significantly different among classes based on t-tests, were selected and included into the classifier. Among them, 92 genes were upregulated in Flt3-ITD class and 55 were downregulated. When the 147-gene list was applied to hierarchical clustering of the 14 Flt3-ITD and -WT specimens, all samples except case 19 were correctly clustered (Figure 3a) . Multidimensional visualization by PCA was also used to observe the spatial distribution of sample clusters in multidimensional space. As shown in Figure 3b , the visualization of highdimensional data in three-dimensional principal components reveals two major distant clusters, Flt3-ITD and Flt3-WT. Interestingly, two cases among Flt3-ITD patients appeared nearer to Flt3-WT cluster than others. A partial list of differentially expressed genes rank-ordered on the basis of main functions is shown in Table 4 . A full list is included in GEO web site (Supplement 7). Second, the Bayesian classifier developed a discriminative function based on the most different genes between Flt3-ITD and -WT classes. The performance of the constructed classifier was assessed by leave-one-out crossvalidation testing method. Briefly, each sample is excluded from the training set one at a time and then classified on the basis of the predictor built from the data for all of the other samples. All the steps of the Bayesian classifier method underwent the crossvalidation procedure. 24 The 147-gene classifier assigned 12 of the 13 samples into the correct class (accuracy ¼ 92%). The fraction of incorrectly classified training observations (error rate) was 0.077.
Altered expression of 147 genes mainly differentiates
Flt3-ITD from Flt3-WT patients Data analysis suggested Flt3-ITDs gene as the main source of gene expression variability in our APL patients. To better identify those genes distinguishing the Flt3-ITD leukaemic cells from Flt3-WT, we applied a Bayesian classifier. The Bayesian algorithm was carried out defining two training classes, one consisted of all Flt3-ITD samples and the other contained all but one Flt3-WT cases (case 19 was
Characterization of differentially expressed genes between Flt3-ITD and -WT APL subsets
Flt3 ITDs gene expression signature consisted of several highexpressed genes, among them we found a group of genes involved in the inflammation and coagulation pathways (Blood Coagulation gene cluster) ( Table 4) . [25] [26] [27] [28] [29] [30] [31] In particular, genes involved in vasodilatation and vascular permeability as PTGIR, NPR1 were up-regulated in Flt3-ITDs subset. We also identified CFH, HFL1 and FHR-3, belonging to human Factor H protein family, which are involved in the inhibition of complement activation. Their overexpression in certain tumour cells such as glioblastoma, ovarian tumour and non-small lung cancer confers an exceptional resistance to such cells against comple- Expression profiling and Flt3 status in APL R Marasca et al ment-mediated lysis. Furthermore, we found high expression of genes involved in coagulation pathway such as PTX3, which upregulates tissue factor expression in endothelial cells, H963, platelet-activating receptor homolog and MMRN1. Another group of genes overexpressed in APL with internal duplications in the Flt3 gene with respect to the wild-type Flt3 were related to proliferation and cell adhesion/invasiveness (Hyperleukocytosis gene cluster) ( Table 4) . [32] [33] [34] Briefly, we found genes for structural constituents of the cytoskeleton and nuclear lamina as VIM, TUBA6, tubulin b and LMNA and genes involved in cytoskeletal remodelling and cell adhesion/migration, usually in association with the inflammatory process, such as CAPN2, AMIGO2 and MMP19. In particular, S100A10 and S100A4, genes of S100 Ca þ binding family, play an important role in plasmin production, which is involved in both the stimulation of inflammation and in cancer invasiveness and metastasis. Moreover, we identified a group of genes inducing cell proliferation (LDLR, LRP8, HMGCS1, CRIP1, hCRHP, LRRFIP2, SFRP4). [35] [36] [37] [38] [39] In particular, elevated levels of low-density lipoprotein receptors (LDLR and LRP8) were reported in proliferating normal cells and tumours. Finally, we found several genes involved in embryogenesis (MEF2C, BAPX1, GLI2, HLX1, PMP22, EMP1, TAGLN2) ( Table 4) . On the other hand, a group of 55 genes were found to be downregulated in leukaemic populations harbouring Flt3-ITDs with respect to cases with Flt3 in the wildtype configuration. Among these genes, we identified BPI, CTSF, CAMP, EPX, LTF and LCN2 coding antimicrobial proteins contained within granules 40 as well as a group of genes involved in the control of differentiation such as NELL2, 41 CREG, 42 PPARG, 43 TLE1 44 and five genes expressed in erythrocytes (RHD, RHCE, SPTA1, GYPC, GYPA) ( Table 4 and Supplement 7).
Discussion
Distinct features defined by cytomorphology, immunophenotype, cytogenetics and molecular genetics parameters identify specific gene expression patterns of acute leukaemias. In particular, AML with specific reciprocal rearrangements can be recognized on the basis of different gene expression patterns. Interestingly, APL cases, characterized by t(15;17) chromosome translocation, have a highly homogeneous expression pattern, whereas cases with t(8;21) or inv(16) are less well correlated. 2, 3 Despite the fact that APL is a well-characterized disease, with a well-defined pathogenetic and clinical picture as well as an established therapeutic strategy based on ATRA combined with chemotherapy, several aspects of variability characterize the disease at a phenotypic or at a haematological level, that is, M3 or M3v morphology, cytopenia or leukocytosis, intensity of disseminated intravascular coagulation (DIC) and platelet count. Of importance, initial leukocytes and platelet counts are considered important factors influencing the relapse-free survival allowing to stratify APL patients into different prognostic groups. 45 Moreover, this variability is also observed at a molecular level, substantially represented by the presence of different PML breakpoints with different PML/RARa transcripts and by the presence of Flt3 mutations. Interestingly, Flt3-ITDs appear to be frequently associated to leukocytosis, M3v form and to the presence of the short PML/RARa isoform (bcr3). 13, 16, 22, 46 We decided to examine the gene expression profiles by microarray containing approximately 20 000 human genes of 18 t(15;17) APL cases looking for correlation with clinical, morphological, and molecular features. As expected, APL demonstrated a homogeneous pattern of gene expression (Figure 1a) characterized by a very high correlation coefficient (Pearson correlation coefficient range ¼ 0.90-0.98) among all the samples examined. Nevertheless, robust differences in the expression levels of some genes enabled the division of APL patients into two major and one minor cluster with hierarchical unsupervised analysis. Of relevance, the two principal clusters of APL patients identified by two-dimensional unsupervised clustering were characterized by a preferential distribution of the haematological and molecular parameters examined and, in particular, Cluster I was mainly represented by cases with M3v morphology, high leukocyte count, bcr3 PML/RARa (short type) 23 This is therefore consistent with the presence of an APL subtype, clearly identifiable with unsupervised gene expression analysis, corresponding substantially to a M3v form with Flt3-ITDs. Nevertheless, some exceptions in cluster constitution were present. Case 19, a classic M3 APL patient with Flt3 in a wild-type configuration, but characterized by a leukocyte count higher than 10.000 Â 10 6 /l and a bcr3 PML/RARa isoform, cosegregated into Cluster I among Flt3-ITD/ M3v samples suggesting the presence of some unknown factors determining a very similar expression pattern to Flt3-ITDs cases, that is, the presence of an undetectable Flt3-activating mutation as well as an alteration of a regulatory factor downstream of or linked to the Flt3 pathway. Moreover, two M3v cases, but Flt3-WT, cosegregated into Cluster II among classic APL, suggesting that the main feature determining gene expression patterns could be Flt3 gene status independent of morphological variability.
In order to examine the causal factors involved in gene expression variability in APL, ANOVA analysis was performed. It clearly indicated that almost half genes differentially expressed between the two main clusters (I and II) were related to the Flt3 status, especially when strong statistical criteria were applied. In fact, among 396 genes that better distinguished the two APL clusters identified by unsupervised analysis, we found 171 genes (49%) of Flt3-ITD signature, and only a few genes of M3v and bcr signatures, equal to 16 and 26%, respectively.
Very recently, Haferlach et al 47 published the gene expression analysis by microarray of a cohort of APL patients identifying, by a supervised analysis, a group of genes able to distinguish M3 from M3v cases. They also found that genes that better discriminate M3 from M3v are not substantially related to Flt3-ITD. Our results are substantially in agreement with these observations. In fact, as shown in Figure 2a , only a minority of genes whose expression correlates with morphology or Flt3 status belongs to both groups, suggesting that morphology and FLT3 status, may, at least partly, affect gene expression independently.
As FLT3-ITD plays an important role in APL gene expression profile and is supposed to play a pathogenetic role in acute leukaemia, we identified those genes that are affected by Flt3-ITD status. A Bayesian classifier was constructed with a panel of 147 differentially expressed genes, and in particular 92 genes were upregulated and 55 were downregulated in Flt3-ITDs cases (Figure 3 ). Among the differentially expressed genes, some homogeneous groups were identified involving specific cellular functions that could explain the phenotypic and haematological differences in APL patients correlated to the presence of Flt3-ITDs. In particular, we identified a group of genes, indicated as hyperleukocytosis gene cluster, related to cell adhesion and invasiveness that could explain the observed correlation between Flt3-ITDs and leukocytosis. More specifically, it included genes involved in cytoskeleton organization, cell adhesion as well as cancer invasiveness and metastasis. Moreover, high expression of several genes involved in the inflammation/coagulation process (blood coagulation gene cluster) was found, despite the absence of statistical correlation with the presence of DIC in our cohort. In addition, we also identified several genes involved in embryogenesis and cell growth, which were upregulated in Flt3-ITDs APL cases. On the other hand, among downregulated genes in Flt3-ITDs cases, we found genes expressed along the hematopoietic differentiation pathway, encoding for proteins present in granulocytic granules. It was perfectly concordant with the observed correlation existing between Flt3-ITDs and the hypogranular variant form of APL. Acute promyelocytic leukaemia is characterized by [48] [49] [50] Recently, a pivotal role of Flt3-ITDs constitutive activation was demonstrated in determining a blockage of myeloid differentiation in 32Dcl3 (32D) myeloblastic cell line. 51 The mechanism inducing such differentiation failure in Flt3-ITDs transduced 32D cells involves suppression of C/EBPa and PU.1 expression, which are essential genes needed for the full commitment and differentiation of granulocyte lineage. 52, 53 Moreover, Pim-1 and Pim-2 upregulation was suggested to contribute to proliferative and antiapoptotic pathways induced by Flt3-ITDs signalling. 53, 54 Both C/EBPa, PU.1 downregulation and Pim-1, Pim-2 upregulation were not found in our Flt3-ITDs patients suggesting that other differentiation blockages and proliferative mechanisms must be hypothesized in Flt3-ITD APL in vivo. We can not obviously exclude an alteration of their functions at protein levels. Interestingly, here we found that the expression of crucial genes involved in hematopoietic differentiation such as PPARG and TLE1 was suppressed in Flt3-ITD leukaemic cells. In particular, TLE1/groucho is a crucial corepressor of RUNX genes and of Wnt signalling pathway. 44, 55, 56 Remarkably, RUNX1/AML1 gene (runt-related transcription factor I/acute myeloid leukaemia 1) plays an important role in the regulation of the expression level of many genes involved in hematopoietic cell development; the impairment of AML1 function deregulates the pathways leading to cell proliferation and differentiation and thus seems to contribute to tumoral transformation. [57] [58] [59] On the other hand, Wnt (Winglesstype) signalling pathway has been implicated in self-renewal and proliferation of hematopoietic stem cells and the deregulation of its function is associated with several human cancers. 60 Notably, Flt3-ITD and Wnt signalling pathways have recently been proposed as integrated transforming events in AML. 61 Nevertheless, additional experiments must be conducted to unravel the precise role, if any, of TLE1 in APL.
In conclusion, different genetic and phenotypic alterations concurrently modify the APL gene expression pattern, so consistently as to determine the generation of two APL subtypes. Nevertheless, a role of Flt3-ITDs as a second genetic lesion, which cooperates with PML/RARa in leukaemic transformation in a subset of APL patients, is suggested by several converging elements represented by its association with several clinical or haematologic features, by data deriving from transgenic animal APL models as well as by experiments indicating a disrupted control of differentiation and proliferation in Flt3-ITD myeloid leukaemia cell lines. In this paper, the reported gene expression profile analysis gives further support to this hypothesis also identifying several interesting genes whose expression levels are significantly different on the basis of Flt3 status. 
